Good morning, Dr. Berthiaume. In your presentation, you said that you got additional information on risks from drugs, that the risks are becoming known, and that you often check with other agencies elsewhere because they are often tested on a larger scale. That leads me to ask you a question on Gardasil.
When you hear that, in some countries, young girls are dying—there is no proof yet, but even so—that vaccination continues on a massive scale in Canada, and that, above all, tests have not been done on girls for whom the vaccine is intended, that is, young girls from 9 to 12, what is Health Canada's reaction? I know that, at the moment, responsibility lies with the Public Health Agency. Its vaccination program is huge. But at the same time, you are also involved because Gardasil is a marketed product. It is on the market, and it is intended for children younger than those who were used to test it. There are serious complications, that, for some young girls, can mean death.
What is your link with other regulators in the countries where that has happened? What decisions do you need to make to reassure people? What do you tell mothers who give consent for their daughters to get the vaccine? I understand that children need their mother's consent to get it. How do you tell parents that the vaccine poses a risk?